Clinical trials: Glaucoma, Open-Angle Glaucoma Eye
Open-angle Glaucoma, Ocular Hypertension
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
- Trial name
- NCT06267274
- Testing
- Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Glaucoma, Open-Angle, Glaucoma
iStent Inject New Enrollment Post-Approval Study
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
- Trial name
- NCT04624698
- Testing
- iStent Inject Implantation
- Where
- 3 sites in United States
- Volunteers
- 358 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Glaucoma, Primary Open Angle
Evaluation the Safety and Effectiveness of the GORE GDI in Adult Subjects With Primary Open-angle Glaucoma in Whom Previous Medical and Surgical Treatment Have Failed.
Evaluation the Safety and Effectiveness of the GORE GDI in Adult Subjects With Primary Open-angle Glaucoma in Whom Previous Medical and Surgical Treatment Have Failed.
- Trial name
- NCT07880132
- Testing
- GORE Glaucoma Drainage Implant
- Volunteers
- 70 people
- Sponsor
- Gore Ophthalmic
Ocular Hypertension, Open Angle Glaucoma
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin…
- Trial name
- NCT01937299
- Testing
- Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Travoprost 0.004% ophthalmic solution
- Volunteers
- 307 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
- Trial name
- NCT06223048
- Testing
- AMDX-2011P
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amydis Inc.
Glaucoma, Open-Angle, Ocular Hypertension
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular…
- Trial name
- NCT01735214
- Testing
- Prostaglandin Analogue -Containing IOP-Lowering Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 358 people
- Sponsor
- Allergan
Ocular Hypertension, Open Angle Glaucoma
Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)
To evaluate if preservative free cosopt is well tolerated in patients with Open angle glaucoma (OAG) or Ocular hypertension (OH) with dry eyes.
- Trial name
- DISCOVER (NCT00545064)
- Testing
- dorzolamide hydrochloride (+) timolol maleate
- Volunteers
- 176 people
- Sponsor
- Merck Sharp & Dohme LLC
Cataract, Ocular Hypertension
Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma
The goal of this clinical trial is to learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma.
- Conditions
- Cataract, Ocular Hypertension, Glaucoma
- Trial name
- NCT07154797
- Testing
- Bimatoprost Implant System / IOL Combination
- Where
- Honduras
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.
- Trial name
- NCT00150267
- Testing
- Xalacom
- Where
- 74 sites in Australia, Belgium and 10 more
- Volunteers
- 976 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle
Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)
First, to compare safety and effectiveness outcomes for canaloplasty and trabeculotomy using the OMNI Surgical System to implantation of the iStent inject in lowering intraocular pressure (IOP) in pseudophakic eyes with open…
- Trial name
- NCT04658095
- Testing
- Canaloplasty and trabeculotomy with the OMNI system., iStent inject, Canaloplasty
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 10 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP…
- Trial name
- NCT01722604
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Primary Open-angle Glaucoma
Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-IO system in patients with Primary Open Angle Glaucoma (POAG)
- Trial name
- NCT03651336
- Testing
- ARGOS-IO Sensor Pressure System
- Where
- 4 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07075718
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
Study of Exchange of Travoprost Intraocular Implant
The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04615403
- Testing
- Travoprost
- Where
- 14 sites in United States, Philippines
- Volunteers
- 33 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Phase IV randomized, double blind, multicenter, parallel group clinical study to evaluate the efficacy of the combined use of Krytantek Ofteno PF® and Gaap Ofteno PF®, both applied every 12 hours, versus the use of Eliptic Ofteno…
- Trial name
- PRO-122 (NCT04702789)
- Testing
- Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Primary Open Angle Glaucoma, Pigmentary Glaucoma
Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study
The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.
- Conditions
- Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT02355990
- Testing
- Minimally Invasive Micro Sclerostomy
- Where
- Israel
- Volunteers
- 96 people
- Sponsor
- Sanoculis Ltd
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
The goal of this study is to compare efficacy and safety of Dorzol 20 mg/mL Eye Drops manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973305
- Testing
- Dorzol 20 mg/ml, Trusopt 20 mg/ml
- Where
- Russia
- Volunteers
- 118 people
- Sponsor
- Jadran Galenski laboratorij d.d.
Ocular Hypertension, Glaucoma
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
The purpose of this study is to demonstrate that fixed combination of latanoprost and timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.
- Conditions
- Ocular Hypertension, Glaucoma, Open-angle Glaucoma
- Trial name
- NCT00856622
- Testing
- i. Fixed combination of latanoprost 0.005% and timolol 0.5%, timolol 0.5% ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 37 sites in Germany
- Volunteers
- 436 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.